Journal
MOLECULAR CANCER THERAPEUTICS
Volume 14, Issue 6, Pages 1454-1465Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-14-1053
Keywords
-
Categories
Funding
- Spanish Ministry of Economy and Competitivity
- ISCIII - FEDER from Regional Development European Funds (European Union) [Fis: PI12/00137, RTICC: RD12/0036/0028]
- Consejeria de Ciencia e Innovacion [CTS-6844, CTS-1848]
- Consejeria de Salud of the Junta de Andalucia [PI-0135-2010, PI-0306-2012]
- FEDER funds
- Juan de la Cierva Fellowship from the Spanish Ministry of Economy and Competitivity
- ISCIII [PIE13/0004]
Ask authors/readers for more resources
MAP17 is a small nonglycosylated membrane protein that is overexpressed in a high percentage of carcinomas. High levels of MAP17 enhance the tumorigenic properties of tumor cells by increasing oxidative stress, which is dependent on Na+-coupled cotransport. Here, we show that MAP17 is associated with proteins involved in protein degradation and that proteasome inhibition induces autophagy. To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors. We provide evidence that bortezomib induces a cytoprotective effect by activating autophagy and NF kappa B nuclear translocation, responses that are repressed in the presence of high levels of MAP17 both in vitro and in vivo. Indeed, patients with multiple myeloma treated with bortezomib showed higher response rates and a longer time to progression associated with increased levels of MAP17 expression. The MAP17-induced sensitivity to bortezomib is dependent on the oxidative status of the cells and the activity of Na+-coupled transporters because treatment with antioxidants or the inhibitor furosemide restores the cytoprotective activity induced by bortezomib. Therefore, bortezomib induces a prosurvival response through cytoprotective autophagy and NF kappa B nuclear translocation, which is repressed by high levels of MAP17. We propose that the levels of MAP17 could be used as a prognostic marker to predict the response to bortezomib in hematologic malignancies and in other tissues that are not commonly responsive to the drug. (C) 2015 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available